Key Positives From The 3Q Results
9M cumulative revenue came in at JPY 564M (+48.4% YoY), led by revenue recognized on new PHR services for pharmaceutical companies. Gross profit rose by JPY 130M, outpacing the JPY 81M increase in SG&A, and the operating loss narrowed by JPY 49M. Separately, WHS's JPY 680M third-party allotment to TISI (payment date 2026/11/30) both expands regional solutions and strengthens the capital base.
- Disease Solutions Service: Revenue reached JPY 327M (+72.4% YoY). Coverage now spans autoimmune diseases, rare diseases and oncology, and the broader revenue pipeline is showing up in the numbers.
- Gross Profit Margin: GPM rose to 69.4% (+0.7pt). Management attributes the gain to platform development investment, which has lowered development costs.
- 3Q Standalone: Revenue was JPY 188M, roughly double the prior-year JPY 92M. The 3Q standalone operating loss narrowed to JPY -115M from JPY -172M a year earlier (both our estimates).
- Work-in-Process and Contract Liabilities: Work-in-process rose to JPY 81M (JPY 3M at start of FY), and contract liabilities, including deferred revenue, climbed to JPY 128M (JPY 56M at start of FY). The build-up reflects project progress and larger advance receipts, laying the groundwork for 4Q revenue recognition.
- TISI Partnership: The business alliance with TISI will launch the rollout of "Healthcare Passport plus", leveraging the customer bases of all three companies. It positions the company for a regional healthcare collaboration business that offers continuous support from wellness and pre-symptomatic care through treatment and nursing care.
Key Concerns From The 3Q Results
Progress stands at 38.5% of the full-year revenue plan of JPY 1,466M (our estimate), so hitting the plan depends heavily on large 4Q bookings. On the balance sheet, WHS's JPY 680M third-party allotment (payment date November 30, 2026) should lift consolidated net assets to around JPY 722M on a simple aggregation basis (our estimate).
- 4Q Hurdle: Meeting full-year guidance requires 4Q standalone revenue of JPY 902M, about 3.5x the prior-year 4Q (JPY 255M). It also requires a 4Q standalone operating profit of JPY +341M (both our estimates).
- Liquidity: Cash and deposits stood at JPY 244M, down JPY 467M from the start of the FY. Borrowings due within one year total JPY 213M. A further JPY 317M of convertible bonds with stock acquisition rights remains outstanding.
- Quality of Bottom-Line Improvement: The JPY 86M narrowing of the net loss includes a swing in profit attributable to non-controlling interests, from JPY +7M last year to JPY -25M this period. The underlying improvement is better measured by the JPY 49M at the operating level.
- Dilution of WHS Stake: The company's stake in WHS falls to 61.67% post-allotment, reducing the share of WHS's future earnings attributable to owners of the parent. This trade-off against revenue gains from the partnership warrants scrutiny. WHS will remain a consolidated subsidiary.
- Platform Provision Lead Times: Order lead times in Platform Provision are lengthening as deals grow larger, creating a risk that revenue recognition slips. Whether larger deals lift revenue per customer also warrants scrutiny.
Focus Areas / Items To Monitor Going Forward
- Scale of 4Q Revenue Recognition: 4Q revenue is concentrated around the fiscal year-ends of foreign pharma clients. We will watch how far the build-up in work-in-process and contract liabilities converts into 4Q revenue and supports the full-year operating loss target of JPY -30M.
- WHS Capital Increase: Completion of payment (2026/11/30) and the resulting consolidated net assets. We will track how far the equity ratio recovers.
- TISI Partnership Contribution: The rollout timing of "Healthcare Passport plus" and the pace at which solutions for insurers and municipalities are monetized.
- Visibility of the large 4Q deals underpinning the JPY 1,466M full-year plan, and how they map to work-in-process and contract liabilities
- Allocation of the JPY 680M raised by WHS and the policy for deploying funds across the group
- Capital-strengthening measures at the parent level and the funding plan, including refinancing of JPY 200M in short-term borrowings
- The revenue model for "Healthcare Passport plus" under the TISI partnership and the timing of its revenue contribution
- Steps to address longer order lead times in Platform Provision and the order outlook for large deals
Key Financial Highlights
| Item | Value | YoY |
|---|---|---|
| Revenue | JPY 564M | +48.4% |
| └ Disease Solutions Service | JPY 327M | +72.4% |
| └ Welby My Karte Service | JPY 237M | +24.6% |
| Gross Profit | JPY 391M | +50.0% |
| Gross Profit Margin | 69.4% | +0.7pt |
| SG&A | JPY 763M | +12.0% |
| └ o/w Upfront Investment in My Karte / Platform Development, etc. | JPY 175M | - |
| Operating Income | JPY -371M | Prior Year: JPY -421M |
| Recurring Profit | JPY -373M | Prior Year: JPY -422M |
| Quarterly Net Income Attributable to Owners of Parent Company | JPY -329M | Prior Year: JPY -415M |
| └ Quarterly Net Income Attributable to Non-Controlling Interests | JPY -25M | Prior Year: JPY +7M |
| EPS | JPY -39.13 | Prior Year: JPY -50.23 |
| Registered Primary Care Medical Institutions | 34,485 Facilities | As of End-Sep 2026 |
| Total App Downloads | Approx. 1.26M | As of End-Sep 2026 |
SG&A fell to 135.3% of revenue from 179.3% a year earlier (our estimate), as top-line growth absorbed the fixed-cost burden. Extraordinary income of JPY 19M came from a gain on reversal of stock acquisition rights, versus JPY 14M in the prior year.
Performance By Business Segment
The company reports a single segment, the PHR Platform Service Business. By service line, Disease Solutions accounted for 57.9% of revenue and about 75% of the revenue increase (our estimate).
Segment Performance Table
| Segment | Revenue | YoY | Operating Income | YoY | Margin |
|---|---|---|---|---|---|
| PHR Platform Service Business | JPY 564M | +48.4% | JPY -371M | Loss Narrowed | -65.9% |
- Disease Solutions Service: Revenue grew 72.4% YoY on recognition of new PHR services ordered by pharmaceutical companies. Use as PSP and ePRO tools is spreading across a widening range of disease areas. In oncology, demand is emerging for monitoring symptoms and side effects of new drugs.
- Welby My Karte Service: Revenue grew 24.6% YoY, driven by new PHR platform deployments and enhanced core functionality. Partnerships with Suzuken, Fukuda Denshi and Chubu Electric Power, together with tie-ups with blood glucose meter manufacturers, are driving adoption among medical institutions.
- None
Progress Versus Full-Year Guidance
Revenue progress stands at 38.5%, below the 59.9% recorded a year earlier (our estimate). The company plan assumes roughly 60% of annual revenue is booked in 4Q. The build-up in work-in-process and contract liabilities is a tailwind. However, 4Q has accounted for only 39.8%–43.7% of annual revenue over the past three fiscal years, so bookings must far exceed that range. On operating income, the plan calls for improvement from JPY -371M for 9M to JPY -30M for the full year.
| Item | Value (9M Cumulative) | Full-Year Forecast | Progress Rate |
|---|---|---|---|
| Revenue | JPY 564M | JPY 1,466M | 38.5% |
| Operating Income | JPY -371M | JPY -30M | - |
- Revenue is heavily weighted to 4Q, when fiscal year-ends of key foreign pharma clients cluster. 4Q accounted for 39.8% of annual revenue in FY12/2023, 43.7% in FY12/2024 and 40.1% in FY12/2025.
- Fixed costs such as SG&A are broadly flat through the year, so profits also tend to skew toward 4Q.
Changes To Guidance
Full-year guidance is unchanged from the figures announced on February 24, 2026 (revenue of JPY 1,466M; operating income of JPY -30M). The plan still assumes large 4Q bookings, so the assessment of this fiscal year will hinge on actual 4Q results.
Commentary On Shareholder Returns
The FY12/2026 dividend forecast is JPY 0.00, unchanged from the prior year (no dividend). There was no revision to the dividend forecast and no mention of share buybacks.
Financial Position
Post-period capital measures should substantially strengthen the balance sheet. Once WHS's JPY 680M third-party allotment is paid in (payment date November 30, 2026), consolidated cash and net assets will rise sharply. On a simple aggregation basis, cash and deposits would reach JPY 924M and net assets JPY 722M (our estimates).
- Key Figures
- Leverage Metrics
| Item | Value | Additional Information |
|---|---|---|
| Cash and Deposits | JPY 244M | -65.7% vs. prior FY-end |
| Shareholders' Equity | JPY 1M | -99.4% vs. prior FY-end |
| Net Assets | JPY 42M | -86.1% vs. prior FY-end |
| Interest-Bearing Debt | JPY 530M | -12.4% vs. prior FY-end; includes convertible bonds |
| └ Short-Term Borrowings | JPY 200M | None at prior FY-end |
| └ Current Portion of Long-Term Borrowings | JPY 13M | JPY 217M at prior FY-end |
| └ Convertible Bonds with Stock Acquisition Rights | JPY 317M | JPY -60M from exercise of conversion rights |
| Work-in-Process | JPY 81M | JPY 3M at prior FY-end |
| Contract Liabilities | JPY 128M | +127.2% vs. prior FY-end |
| EBITDA | JPY -351M | Operating income + depreciation + goodwill amortization; our estimate |
| (Reference) Cash and Deposits After WHS Capital Increase | JPY 924M | Simple aggregation; our estimate |
| (Reference) Net Assets After WHS Capital Increase | JPY 722M | Simple aggregation; our estimate |
| Metric | Value | Notes |
|---|---|---|
| Debt/Equity | 392.2x | Our estimate; extreme value due to shareholders' equity of only JPY 1M |
| Equity Ratio | 0.2% | Company disclosure; 20.9% at prior FY-end |
Disclosures Released Alongside The Earnings Announcement
None
Major Announcements During The Quarter
- 2026/08/28Released its 2Q earnings presentation, covering the business plan and growth potential
- 2026/09/15Resolved a third-party allotment of new shares to Representative Director Takeshi Hiki, raising both share capital and capital surplus by JPY 25M each
- 2026/10/07Disclosed the share transfer reporting commitment related to the above third-party allotment
- 2026/10/20Resolved a business alliance with TISI and a JPY 680M third-party allotment by WHS to TISI. WHS will become an equity-method affiliate of TISI, with the aim of expanding the regional healthcare collaboration business
Large-Shareholding Filings / Material Proposals Over The Past Year
- Milestone Capital Management: New → 19.9% (2025/12/01) - Pure investment
- Milestone Capital Management: 19.9% → 19.7% (2026/03/13) - Pure investment; breakdown of shareholdings changed by 1% or more
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.

